Microneedle devices and methods

A microneedle and medical device technology, applied in the direction of microneedles, needles, pharmaceutical formulations, etc., can solve the problem of expensive system manufacturing

Active Publication Date: 2016-01-20
3M INNOVATIVE PROPERTIES CO
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Such systems are significantly more expensive to manufacture

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Microneedle devices and methods
  • Microneedle devices and methods
  • Microneedle devices and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0174] Preparations containing lidocaine and clonidine

[0175] The microneedle array uses a surface area of ​​about 1.27 cm 2 Class VI medical grade liquid crystal polymer (LCP) ( MT1300, injection molded from Ticona Plastics, Auburn Hills, Michigan, USA (3M Company, St. Paul, MN, USA). Each microneedle array is characterized by 316 quadrangular pyramidal microneedles arranged in an octagonal pattern, where the height of the microneedles is nominally 500 μm, the aspect ratio is about 3:1, and the tips between adjacent microneedles reach The tip distance is nominally 550 microns.

[0176] Using the dip-coating method, a mixture of 30% dextran (Pharmacosmos, Holbaek, Denmark), 30% lidocaine hydrochloride (Sigma-Aldrich, St. Sigma, St. Louis, MO)) and 0.3% clonidine hydrochloride (Spectrum Chemical & Laboratory Products, New Brunswick, NJ, USA (Spectrum Chemical & Laboratory Products, New Brunswick, NJ)), lidocaine was coated onto the microneedle array. Prior to coating, ...

example 2

[0187] Preparations containing lidocaine and epinephrine

[0188] The microneedle array uses a surface area of ​​about 1.27 cm 2 Class VI medical grade liquid crystal polymer (LCP) ( MT1300, injection molded from Ticona Plastics, Auburn Hills, Michigan, USA (3M Company, St. Paul, MN, USA). Each microneedle array is characterized by 316 quadrangular pyramidal microneedles arranged in an octagonal pattern, where the height of the microneedles is nominally 500 μm, the aspect ratio is about 3:1, and the tips between adjacent microneedles reach The tip distance is nominally 550 microns.

[0189] A mixture of 30% dextran (Pharmacosmos, Holbaek, Denmark), 30% lidocaine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was used by dip coating. Sigma, St.Louis, MO)) and 0.03% epinephrine tartrate (Sigma, St.Louis, MO, USA, Sigma, St.Louis, MO) to apply lidocaine to the microneedle array superior. Prior to coating, microneedle arrays were cleaned with 70% isopropanol (BDH, West ...

example 3

[0200] Preparations containing prilocaine and clonidine

[0201] The microneedle array uses a surface area of ​​about 1.27 cm 2 Class VI medical grade liquid crystal polymer (LCP) ( MT1300, injection molded from Ticona Plastics, Auburn Hills, Michigan, USA (3M Company, St. Paul, MN, USA). Each microneedle array is characterized by 316 quadrangular pyramidal microneedles arranged in an octagonal pattern, where the height of the microneedles is nominally 500 μm, the aspect ratio is about 3:1, and the tips between adjacent microneedles reach The tip distance is nominally 550 microns.

[0202] A mixture of 30% dextran (Pharmacosmos, Holbaek, Denmark), 15% prilocaine hydrochloride (Spectrum Chemical & Laboratory Products, New Brunswick, NJ, USA) was used by dip coating. Spectrum Chemical & Laboratory Products, New Brunswick, NJ)) and 0.15% clonidine hydrochloride (Spectrum Chemical & Laboratory Products of New Brunswick, New Jersey, USA (Spectrum Chemical & Laboratory Product...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a medical device, which comprises: a microneedle array, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from lidocaine, Prilocaine and combinations thereof; and a local anesthetic dose sustained release component selected from the group consisting of alpha 1 adrenergic agonists, alpha 2 adrenergic agonists and combinations thereof; wherein based on the coating The total weight of solids, the local anesthetic is present in an amount of at least 1% by weight, and wherein the dose-extending component / local anesthetic weight ratio is at least 0.0001; a medical device comprising An array of dissolving microneedles comprising: a dissolvable matrix material; at least 1% by weight of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and combinations thereof; and a local anesthetic dose sustained release component , the local anesthetic dose-sustaining release component is selected from α1 adrenergic agonist, α2 adrenergic agonist and combinations thereof; wherein the weight ratio of the dose-sustaining component / local anesthetic is at least 0.0001, and wherein the weight % based on the total weight of solids in all portions of the dissolvable microneedles containing the local anesthetic; a method of using the device to provide sustained release of a locally delivered dose of local anesthetic in mammalian tissue; and a method of manufacturing method of the device.

Description

[0001] This application claims the benefit of US Provisional Application No. 61 / 449,993, filed March 7, 2011, which is hereby incorporated by reference in its entirety. Background technique [0002] Transdermal delivery of therapeutic agents (eg, drugs) through the skin to local tissues or the systemic circulatory system without piercing the skin, such as using transdermal patches, has been used successfully in some pharmaceuticals. This type of passive delivery involves diffusion of the agent across at least the stratum corneum, where the rate of diffusion through the stratum corneum can be rate limiting. [0003] Active delivery of therapeutic agents is practiced in certain instances to increase flux of the agent through the stratum corneum. In this case an external energy source (eg, electrical potential, ultrasound, or heat) is applied to aid transport of the agent through the stratum corneum or through the skin. [0004] The amount of drug delivered transdermally is also...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/00A61M37/00
CPCA61M2037/0023A61M2037/0046A61M37/0015A61M2037/0061A61K9/0021A61P23/02A61P25/02A61P43/00A61K9/00A61M37/00
Inventor 张莹克里斯滕·J·汉森埃米·S·德特曼
Owner 3M INNOVATIVE PROPERTIES CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap